MarketPR
The weight-loss drug rivalry between Novo Nordisk and Eli Lilly is in focus for NVO and LLY holders after Novo Nordisk accused Lilly of deploying outdated data to support claims that Lilly's products are more effective than Wegovy.
The Danish company's framing is direct: the conduct was deceptive. What to watch next is whether the accusation reaches a formal regulatory or legal venue.
The substance of the charge Novo Nordisk's case, as the Danish group has stated it, is that Lilly's marketing materials leaned on data that was no longer current when used to argue comparative effectiveness against Wegovy, which is Novo Nordisk's weight-loss product.
The word "deceptive" is doing significant work in that framing. It moves the dispute from competing commercial claims into territory where regulators and courts become relevant.
Keep reading